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Abstract Sunitinib is a tyrosine kinase inhibitor (TKI) used
in treatment of metastatic renal cell carcinoma (mRCC),
gastrointestinal stromal tumors and pancreatic neuroen-
docrine tumors. One of the most common side effects
related to sunitinib is hypothyroidism. Recent trials suggest
correlation between the incidence of hypothyroidism and
treatment outcome in patients treated with TKI. This study
evaluates whether development of hypothyroidism is a
predictive marker of progression-free survival (PFS) in
patients with mRCC treated with sunitinib. Twenty-seven
patients diagnosed with clear cell mRCC, after nephrectomy
and in ‘good’ or ‘intermediate’ MSKCC risk prognostic
group, were included in the study. All patients received
sunitinib as a first-line treatment on a standard schedule
(initial dose 50 mg/day, 4 weeks on, 2 weeks off). The
thyroid-stimulating hormone serum levels were obtained at
the baseline and every 12 weeks of treatment. In statistic
analyses, we used Kaplan–Meier method for assessment of
progression-free survival; for comparison of survival, we
used log-rank test. In our study, the incidence of hypothy-
roidism was 44%. The patients who had developed
hypothyroidism had better median PFS to patients with
normal thyroid function 28,3 months [95% (CI)
20.4–36.2 months] versus 9.8 months (6.4–13.1 months). In
survival analysis, we perceive that thyroid dysfunction is a
predictive factor of a progression-free survival (PFS). In the
unified group of patients, the development of hypothy-
roidism during treatment with sunitinib is a positive marker
for PFS. During that treatment, thyroid function should be
evaluated regularly.
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Introduction
Sunitinib is an oral inhibitor of multiple tyrosine kinases of
vascular endothelial growth factor receptors (VEGFR1,
VEGFR2 and VEGFR3), platelet-derived growth factor
receptors (PDGFRa and PDGFRb), the stem cell factor
KIT receptor, Fms-3-like tyrosine kinase (FLT3) receptor,
the glial cell line-derived neurotrophic factor receptor
(RET) and colony-stimulating factor 1 receptor (CSF-1R)
[1–3].
Sunitinib was approved by the Food and Drug Admin-
istration (FDA) in treatment of advanced renal cell cancer
(RCC), gastrointestinal stromal tumors (GISTs) and pan-
creatic neuroendocrine tumors [3]. In metastatic clear cell
RCC, it is indicated by ESMO guidelines as a first-line
treatment in patients with ‘good’ or ‘intermediate’ risk
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according to the Memorial Sloane Kettering Cancer Centre
(MSKCC) and Heng criteria [4].
Treatment with the sunitinib is associated with favorable
safety profile. However, as the treatment with other tar-
geted agents, the side effects differ from the standard
chemotherapy. The most common adverse events associ-
ated with the sunitinib treatment are cardiovascular toxicity
(hypertension, decline in left ventricular ejection fraction),
dermatologic toxicity (rash, hand-foot syndrome), fatigue
and asthenia, gastrointestinal toxicity, myelosuppression
and endocrine toxicity (hypothyroidism and adrenal
insufficiency) [5, 6]. Although the severity of occurring
side effects is mainly mild or moderate, they should be
managed directly in order to prevent dose reduction or
withdrawal of the treatment [6]. On the other hand, our
recent study suggested correlation between the number of
sunitinib-induced adverse effects and treatment outcome
(PFS) [7]. Also the several trials confirmed that developing
hypertension during treatment is associated with significant
improvement in response rate, progression-free survival
and overall survival [7–9]. Recent trials suggested corre-
lation between the incidence of hypothyroidism and better
outcome in patients treated with TKI [1, 2, 10]. The fre-
quency of impaired thyroid function during treatment is
estimated of 36–85% [11]. This study evaluates the effect
of one of the most common side effects, hypothyroidism on
efficacy of the treatment with sunitinib in mRCC.
Materials and methods
The retrospective study included 27 patients treated at the
Department of Oncology, University Hospital in Krakow.
The inclusion criteria were as follows: diagnosis of stage
IV clear cell mRCC, application of sunitinib as first-line
treatment for the mRCC, prior nephrectomy (total or
nephron sparing surgery) and good or intermediate
Memorial Sloane Kettering Cancer Centre (MSKCC) risk
prognosis (Table 1). All patients received sunitinib on a
standard schedule (initial dose 50 mg/day, 4 weeks on,
2 weeks off). The thyroid-stimulating hormone (TSH)
serum concentrations were obtained at the baseline and
every 12 weeks (i.e., after every second cycle of treat-
ment). TSH was measured on the day of blood collection
with electrochemiluminescence immunoassay (ECLIA) on
Cobas 600 analyzer (Roche Diagnostics). The reference
interval for TSH was 0.27–4.20 lIU/mL. Hypothyroidism
was defined as serum TSH[ 4.20 lIU/mL. Patients with
hypothyroidism were referred to endocrinologist, and
appropriate treatment was initiated according to the current
guidelines.
We received permission to conduct this study from the
Jagiellonian University Bioethics Committee (Permission
No. KBET/45/B/2013). For this type of study, formal
consent is not required.
Statistical analysis was performed using Statistica 12
software (StatSoft Inc., Tulsa, USA). Data were reported as
number of patients (percentage of the group) for categories
and median (lower–upper quartile) for quantitative vari-
ables. Progression-free survival was counted from the start
of treatment with sunitinib until disease progression or
death from any cause, or was censored at the end of the
study. PFS was estimated with Kaplan–Meier method and
compared with log-rank test. Also, Cox proportional hazard
regression was used to assess independent predictors of
PFS. The tests were two-tailed, and the results at p\ 0.05
were interpreted as statistically significant.
Results
All of the patients included in the study were tested for
thyroid function before starting sunitinib and after every
second course of treatment. None of the patients had pos-
itive medical history for hypothyroidism. Baseline TSH
was within reference interval in all patients: median TSH
before starting sunitinib was 1.56 (1.08–2.00) lIU/mL. In
the course of treatment, serum TSH increased above the
Table 1 Study group
characteristics
Age (years) 65 (59–69)
Gender: women/man [n(%)] 9 (33)/18 (67)
Body mass (kg) 74 (67–84)
BMI (kg/m2) 27 (25–30)
Disseminated disease at baseline [n (%)] 22 (81)
Fuhrman grade[2 [n (%)] 17 (63)
Time from diagnosis to the systemic treatment\1 year [n (%)] 13 (48)
MSKCC prognosis: favorable/intermediate [n (%)] 21 (78)/6 (22)
IMRDC prognosis: favorable/intermediate [n (%)] 19 (70)/8 (30)
ECOG performance status (PS) before the treatment with sunitinib 0/1 [n (%)] 13 (48)/14 (52)
Positive history of hypertension [n (%)] 3 (11)
Positive history of hypothyroidism [n (%)] 0
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upper reference limit in 12 patients (44%). Median TSH
after second cycle of treatment was 4.90 (1.77–10.30) lIU/
mL. The incidence of hypothyroidism during sunitinib
treatment was associated with longer progression-free
survival of 28,3 months [95% (CI) 20.4–36.2 months]
versus 9.8 months (6.4–13.1 months) (p = 0.022) (Fig. 1).
Moreover, the incidence of hypothyroidism predicted PFS
independently of MSKCC score (hazard ratio: 0.37; 95%
CI 0.14–0.98; p = 0.045).
Discussion
The mechanism of thyroid dysfunction during TKI treatment
has been yet not fully defined. The most probable mecha-
nism could be connected with VEGFR blockade. The thy-
roid gland is well vascularized with VEGFR signaling-
dependent blood flow that is crucial for thyroid function.
Sunitinib by inhibiting the VEGFR receptor may influence
on the vascularity of the gland and consequently induce
tissue ischemia, which results in thyroid insufficiency
[2, 12]. Other considered mechanisms are sunitinib-induced
thyrotoxicosis, iodine uptake blocking, increased activity of
deiodinase 3, inhibition of thyroperoxidase and increased
metabolism of levothyroxine [1, 2, 13–18]. One of the recent
studies analyzing hypothyroidism during treatment with
sunitinib and sorafenib suggested a new hypothesis. Study
revealed that sunitinib specifically binds to three retinoid
receptors. Based on the fact that thyroid hormone action is
mediated by thyroid hormone receptors and retinoid acid
receptors, it is possible that sunitinib competes with thyroid
hormone receptors for binding with retinoic acid receptors
which finally results in hormonal dysregulation [19].
In our study, the incidence of hypothyroidism during
sunitinib treatment was 44% (12 patients).
There was a statistically significant difference in median
PFS between patients who developed hypothyroidism and
patients without that side effect. That results suggest that
hypothyroidism incidence during treatment with sunitinib
was a predictive marker of a progression-free survival. The
results are partly similar to the Wolter’s et al. who analyzed
correlation between thyroid dysfunction and treatment out-
come in a group of 40 patients enrolled in the study. Thyroid
dysfunction was observed in 70% of patients, and 32.5% of
them had symptomatic hypothyroidism. Statistical analysis
revealed that thyroid dysfunction was associated with longer
PFS and however was not correlated with OS [20].
Another study that supports our results is Kust et al.’s
survey assessing influence of hypothyroidism on treatment
response to sunitinib therapy. The incidence of hypothy-
roidism in their sample was 29.3%, while in our study—
44%. The patients who developed hypothyroidism and
receive substitution therapy had longer PFS compared to all
other patients (25.3 vs. 9.0 months) [21]. Schmidinger
et al.’s study which assessed clinical impact of hypothy-
roidism in patients with mRCC treated with sunitinib or
sorafenib revealed correlation between hypothyroidism and
percentage of overall response rate. The correlation was
observed in both groups—treated with sunitinib and with
sorafenib. In the group treated with sunitinib, there was no
correlation between hypothyroidism and PFS nor OS.
However, patients enrolled in the study got TKI in the
second-line treatment which is the major difference between
this and our study. Patients included in the study had pro-
gressed on cytokines and/or had received a TKI or mono-
clonal antibody before introducing sunitinib or sorafenib
[10]. Also the TSH level was assessed after the first and
second cycle, and according to recent studies, the time from
beginning of the treatment with sunitinib to the onset of
hypothyroidism is longer. According to Wong et al. [18], the
average development of this side effect is 5 months. Vettel
et al. have reported that the onset of hypothyroidism was
observed between 12 and 50 weeks after initiation of suni-
tinib with growing incidence with treatment prolongation
[11, 22]. Considering the relatively long time of hypothy-
roidism development, the early evaluation of treatment
efficacy is limited. However, it may provide information
about expected PFS in group of patients with occurrence of
impaired thyroid function. In those cases, the supplementa-
tion of levothyroxine should be considered. Sunitinib dose
reduction due to hypothyroidism should be avoided.
Conclusion
Results of our study support previous assumptions about
the correlation between incidence of hypothyroidism and
treatment benefit. We found that in uniform group of
Fig. 1 Cumulative survival in patients who developed hypothy-
roidism during sunitinib treatment (solid line) and those who did not
(dashed line)
Med Oncol (2017) 34:68 Page 3 of 4 68
123
patients (stage IV clear cell mRCC, after total or partial
nephrectomy, ‘good’ or ‘intermediate’ MSKCC risk prog-
nosis and sunitinib as a first-line treatment) the developing
of hypothyroidism is a predictive marker of PFS. Conse-
quently, the thyroid function should be evaluated regularly
during treatment with sunitinib. Thyroid function check
may eliminate the risk of assignment of the typical symp-
toms of hypothyroidism to cancer or to fatigue caused by
sunitinib.
Early detection of hypothyroidism and beginning of
levothyroxine substitution if necessary may avoid treat-
ment interruptions or dose reductions.
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